Table 3.
Multivariate analyses of Overall Survival in Subgroup of Oligometastatic and Polymetastatic Disease.
| Characteristics | OMD | PMD | ||
|---|---|---|---|---|
| HR (95%CI) | P | HR (95%CI) | P | |
| Nasopharyngeal | ||||
| Radiotherapy, No/Yes | 0.413 (0.198–0.861) | 0.018 | 0.934 (0.402–2.172) | 0.875 |
| KPS, ≤80/>80 | 0.742 (0.379–1.456) | 0.742 | 0.559 (0.239–1.312) | 0.182 |
| Chemotherapy cycles, <6/≥6 | 0.706 (0.335–1.490) | 0.361 | 0.419 (0.180–0.997) | 0.977 |
| LDH, Abnormal/Normal | 0.956 (0.402–2.274) | 0.956 | 1.593 (0.739–3.430) | 0.234 |
| EBV DNA,>4000 /<4000 | 1.591 (0.806–3.139) | 0.181 | 0.887 (0.349–2.257) | 0.802 |
Abbreviation: OMD, Oligometastatic Disea; PMD, Polymetastatic Disease; KPS, Karnofsky performance status score; LDH, Lactate dehydrogenase; EBV, Epstein–Barr virus.